Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib versus TNF inhibitor safety study in adults with rheumatoid arthritis at increased VTE risk
MOH_2019-06-11_007193Phase 4Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2019
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of baricitinib in rheumatoid arthritis (RA) (2 arms), sponsored by Eli Lilly and Company. Started Apr 2019; status: active, not recruiting.
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on MOH_2019-06-11_007193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-06-11_007193.